High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40kd) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin

被引：20
|
作者：
Nelson, D. [1 ]
Pockros, P. J. [2 ]
Godofsky, E. [3 ]
Rodriguez-Torres, M. [4 ]
Everson, G. [5 ]
Fried, M. [6 ]
Ghalib, R. [7 ]
Harrison, S. [8 ]
Nyberg, L. [9 ]
Shiffman, M. [10 ]
Chan, A.
Hill, G.
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Scripps Clin, La Jolla, CA 92037 USA
[3] Univ Hepatitis Ctr Bach & Godofsky, Bradenton, FL USA
[4] Fdn Invest Diego, Santurce, PR USA
[5] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[6] Univ N Carolina, Chapel Hill, NC USA
[7] Dallas Methodist Hosp, Liver Inst, Dallas, TX USA
[8] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA
[9] Kaiser Permanente, San Diego, CA USA
[10] Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23284 USA
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60995-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
993
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [21] Peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin in chronic hepatitis C:: Retreatment of patients who relapsed virologically after 24 weeks of therapy.
    Goncales, F
    Bernstein, DE
    Berg, C
    Sette, H
    Rasenack, J
    Diago, M
    Jensen, DM
    Cooksley, WGE
    Roberts, P
    Ackrill, AM
    HEPATOLOGY, 2002, 36 (04) : 361A - 361A
  • [22] Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2a(40KD)(pegasys)alone versus peginterferon alfa-2a plus ribavirin in naive, patients with chronic hepatitis c and genotype I who respond to a 24 week course therapy of peginterferon alfa-2a plus ribavirin: Preliminary results of an open, multicenter randomized trial.
    Bronowicki, JP
    Ouzan, D
    Asselah, T
    Desmorat, H
    Zarski, JP
    Couzigou, P
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Bouvier, M
    Lonjon-Domanec, I
    Neuilly, R
    Pawlotsky, JM
    HEPATOLOGY, 2002, 36 (04) : 293A - 293A
  • [23] Effect of ethnicity on the pharmacokinetics of ribavirin (COPEGUS®) and peginterferon alfa-2a (40kd) (PEGASYS®) in patients with chronic hepatitis C
    Brennan, B
    Morrison, R
    Hagedorn, C
    Marbury, TC
    Sulkowski, M
    Grippo, J
    Gries, JM
    HEPATOLOGY, 2005, 42 (04) : 652A - 653A
  • [24] Utility of virological response at weeks 4 and 12 in the prediction of SVR rates in genotype 2/3 patients treated with Peginterferon alfa-2a (40kd) plus ribavirin: Findings from accelerate
    Shiffman, Mitchell
    Pappas, Stephen
    Bacon, Bruce
    Godofsky, Eliot
    Nelson, David
    Harley, Hugh
    Diago, Moises
    Lin, Amy
    Hooper, Gregory
    Zeuzem, Stefan
    HEPATOLOGY, 2006, 44 (04) : 316A - 317A
  • [25] Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Snoeck, Eric
    Wade, Janet R.
    Duff, Frank
    Lamb, Matthew
    Jorga, Karin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 699 - 709
  • [26] Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1
    Jeffers, LJ
    Cassidy, W
    Howell, CD
    Hu, S
    Reddy, KR
    HEPATOLOGY, 2004, 39 (06) : 1702 - 1708
  • [27] Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
    Pijak, MR
    Gazdik, F
    Hrusovsky, S
    HEPATOLOGY, 2004, 40 (03) : 760 - 761
  • [28] Peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3:: The nordynamic trial
    Lagging, Martin
    Pedersen, Court
    Buhl, Mads Rauning
    Faerkkilae, Martti
    Langeland, Nina
    Morch, Kristine
    Westin, Johan
    Alsioe, Asa
    Norkrans, Gunnar
    HEPATOLOGY, 2007, 46 (04) : 815A - 816A
  • [29] Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response
    Ferenci, Peter
    Laferl, Hermann
    Scherzer, Thomas-Matthias
    Maieron, Andreas
    Hofer, Harald
    Stauber, Rudolf
    Gschwantler, Michael
    Brunner, Harald
    Wenisch, Christoph
    Bischof, Martin
    Strasser, Michael
    Datz, Christian
    Vogel, Wolfgang
    Loeschenberger, Karin
    Steindl-Munda, Petra
    GASTROENTEROLOGY, 2010, 138 (02) : 503 - U126
  • [30] Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    Sherman, M.
    Yoshida, E. M.
    Deschenes, M.
    Krajden, M.
    Bain, V. G.
    Peltekian, K.
    Anderson, F.
    Kaita, K.
    Simonyi, S.
    Balshaw, R.
    Lee, S. S.
    GUT, 2006, 55 (11) : 1631 - 1638
12345